KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Common Equity: 2009-2024

Historic Common Equity for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $588.4 million.

  • Ionis Pharmaceuticals' Common Equity fell 6.72% to $618.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $618.0 million, marking a year-over-year decrease of 6.72%. This contributed to the annual value of $588.4 million for FY2024, which is 52.15% up from last year.
  • As of FY2024, Ionis Pharmaceuticals' Common Equity stood at $588.4 million, which was up 52.15% from $386.7 million recorded in FY2023.
  • Ionis Pharmaceuticals' 5-year Common Equity high stood at $771.7 million for FY2021, and its period low was $386.7 million during FY2023.
  • Its 3-year average for Common Equity is $516.0 million, with a median of $572.9 million in 2022.
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 55.88% in 2020, then skyrocketed by 52.15% in 2024.
  • Ionis Pharmaceuticals' Common Equity (Yearly) stood at $743.3 million in 2020, then grew by 3.83% to $771.7 million in 2021, then declined by 25.77% to $572.9 million in 2022, then tumbled by 32.50% to $386.7 million in 2023, then spiked by 52.15% to $588.4 million in 2024.